from this business segment since then. Trading of consumer products segment This business segment commenced operate by the Company in June 2019. Total sales for the current period increase due to the
-9.9 -24.7% Share of profit from investment in associates 126.8 174.8 -48.0 -27.5% Net Profit 999.3 903.2 96.1 10.6% Million Baht Increase (Decrease) The operating result of the Company for FY 2019/2020
performance Statement of income Consolidated Financial Statements for Quarter 1 of 2020 Quarter 1 of 2019 Change (Unaudited but reviewed) (Unaudited but reviewed) Increase (Decrease) THB Million % THB Million
the third quarter of the previous year which were Baht 211 million. 1.2 Fee and Service income The Company’s fee and service income in the third quarter of 2019 was Baht 212 million, an increase of 22
ending 2018, the total revenue was 2,708.65 Million Baht, which increased by 1,381.52 Million Baht or an increase by 104.10% compared to the same period last year. The key factor was from an increase in
Baht 939.87 million and new share issuance for capital increase of Baht 55 million. Please be informed accordingly. Yours sincerely, Miss Supamas Isarapakdi Chief Executive Officer DOD Biotech Public
increase in loan outstanding used to finance the projects under construction. Please be informed accordingly. Yours sincerely, (Assoc.Prof.Dr.Chalerm Harnphanich, M.D.) Chief Executive Officer
. Tel: 02-0195000 In the 3rd quarter of 2018 and 2019, the Group’s total revenue increased from THB 757.0 Mn to THB 793.2 Mn respectively, an increase of THB 36.2 Mn or 4.8%. And for the nine months
performance Statement of income Consolidated Financial Statements for Quarter 2 of 2019 Quarter 2 of 2018 Change (Unaudited but reviewed) (Unaudited but reviewed) Increase (Decrease) THB Million % THB Million
performance Statement of income Consolidated Financial Statements for Quarter 2 of 2020 Quarter 2 of 2019 Change (Unaudited but reviewed) (Unaudited but reviewed) Increase (Decrease) THB Million % THB Million